Related Experiment Videos
Proteinuria: its clinical importance and role in progressive renal disease
1Department of Medicine, Hennepin County Medical Center, University of Minnesota Medical School, Minneapolis 55415, USA. keane001@tc.umn.edu
Insights
Proteinuria, or excess urinary protein, is a key indicator of cardiovascular and kidney disease risk in hypertensive and diabetic patients. Reducing proteinuria with ACE inhibitors slows kidney function decline.
Area of Science:
- Nephrology
- Cardiology
- Endocrinology
Background:
- Proteinuria is an independent risk factor for cardiovascular morbidity and mortality in patients with hypertension and diabetes.
- These patients exhibit cardiovascular risk factors and endothelial dysfunction, increasing susceptibility to vascular disease.
- Proteinuria predicts chronic and progressive renal insufficiency, independent of other risk factors.
Purpose of the Study:
- To highlight the significance of proteinuria as a predictor of cardiovascular and renal disease.
- To discuss the role of angiotensin-converting enzyme (ACE) inhibitors in managing proteinuria and slowing renal function decline.
- To emphasize the need for multifaceted strategies in managing cardio-renal disease.
Main Methods:
- Review of recent clinical studies and evidence regarding proteinuria.
- Analysis of the impact of proteinuria on cardiovascular and renal outcomes.
- Evaluation of the efficacy of ACE inhibitors in modifying proteinuria and renal function.
Main Results:
- Proteinuria is a significant risk marker for cardiovascular events and progressive renal insufficiency.
- ACE inhibitors slow the rate of renal function loss, independent of blood pressure reduction.
- Proteinuria's negative effects are evident even at lower excretion rates.
Conclusions:
- Managing proteinuria is crucial for slowing chronic kidney disease progression.
- Combined pharmacological and dietary interventions are necessary for optimal renal protection.
- Addressing shared risk factors for cardio-renal disease is essential for improving patient survival.
Abstract:
In patients with essential hypertension and in those with diabetes mellitus, the presence of increased amounts of urinary protein or albumin has been shown to be an important and independent risk for an increased incidence of cardiovascular morbidity and mortality. A constellation of cardiovascular risk factors has been described in these individuals, as well as evidence for diffuse endothelial cell dysfunction, which suggests these individuals are particularly susceptible to the development of extensive vascular disease. Recent studies have also suggested that proteinuria is not only a marker for renal disease but it also predicts those patients at greatest risk for the development of chronic and progressive renal insufficiency. This effect of proteinuria was evident in patients in whom urinary protein excretion rates exceeded 1 g/24 hours, but probably is true even in patients with smaller amounts of proteinuria. This effect of proteinuria on progression of renal disease is independent of other risk factors such as level of renal function, blood pressure, and dyslipidemia. Recent clinical studies have demonstrated that modification of proteinuria by the use of angiotensin-converting enzyme (ACE) inhibitors independent of reductions in systemic blood pressure results in slowing of the rate of loss of renal function and even stabilization of renal function over longer periods of treatment. In patients with renal disease, the totality of evidence suggests that multiple pharmacological and dietary modifications will be necessary to achieve the optimal slowing of the progression of renal disease. In addition, strategies will be required to reduce risks involved in the development of cardiovascular disease to ensure optimal patient survival. The similarity of risk factors involved in cardio-renal disease progression should allow us to achieve this goal with our current therapeutic armamentarium.